| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BRISTOL MYERS SQUIBB CO | SVP,Head Glob. Medical Affairs | Common Stock, $0.10 par value | 9,485 | $472,163 | $49.78 | 03 Jun 2021 | Direct |
| BRISTOL MYERS SQUIBB CO | SVP,Head Glob. Medical Affairs | Restricted Stock Units | 4,309 | $215,881 | $50.10 | 03 Jun 2021 | Direct |
| GERON CORP | EVP, R&D; Chief Medical Office | Stock Option (Right to Buy) | 2,220,000 | 17 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GERN | GERON CORP | 17 Feb 2026 | 1 | $0 | 4 | EVP, R&D; Chief Medical Office | 19 Feb 2026, 18:11 |
| GERN | GERON CORP | 11 Nov 2024 | 0 | $0 | 3 | EVP, Research and Development | 12 Nov 2024, 16:05 |
| GERN | GERON CORP | 11 Nov 2024 | 1 | $0 | 4 | EVP, Research and Development | 12 Nov 2024, 16:05 |
| BMY | BRISTOL MYERS SQUIBB CO | 03 Jun 2021 | 3 | -$47,822 | 4 | SVP,Head Glob. Medical Affairs | 04 Jun 2021, 16:36 |
| BMY | BRISTOL MYERS SQUIBB CO | 10 May 2021 | 1 | -$72,670 | 4 | SVP,Head Glob. Medical Affairs | 11 May 2021, 16:39 |